Attached files
file | filename |
---|---|
10-K - 10-K - Phathom Pharmaceuticals, Inc. | phat-10k_20201231.htm |
EX-32.2 - EX-32.2 - Phathom Pharmaceuticals, Inc. | phat-ex322_1449.htm |
EX-32.1 - EX-32.1 - Phathom Pharmaceuticals, Inc. | phat-ex321_1450.htm |
EX-31.2 - EX-31.2 - Phathom Pharmaceuticals, Inc. | phat-ex312_1447.htm |
EX-31.1 - EX-31.1 - Phathom Pharmaceuticals, Inc. | phat-ex311_1411.htm |
EX-24.1 - EX-24.1 - Phathom Pharmaceuticals, Inc. | phat-ex241_1587.htm |
EX-10.22 - EX-10.22 - Phathom Pharmaceuticals, Inc. | phat-ex1022_2100.htm |
EX-10.21 - EX-10.21 - Phathom Pharmaceuticals, Inc. | phat-ex1021_1410.htm |
EX-10.20 - EX-10.20 - Phathom Pharmaceuticals, Inc. | phat-ex1020_1409.htm |
EX-4.6 - EX-4.6 - Phathom Pharmaceuticals, Inc. | phat-ex46_8.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
(1) |
Registration Statement (Form S-8 No. 333-234357) pertaining to the 2019 Equity Incentive Plan, 2019 Incentive Award Plan, and 2019 Employee Stock Purchase Plan of Phathom Pharmaceuticals, Inc., and |
|
(2) |
Registration Statement (Form S-3 No. 333-250014) of Phathom Pharmaceuticals, Inc.; |
of our report dated March 30, 2021, with respect to the financial statements of Phathom Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
San Diego, California
March 30, 2021